Chinese researchers plan to begin Phase II trials soon on a new type of vaccine for hepatitis B, using a protein to teach an immune response instead of the usual treatment with interferon. The protein vaccine has been found to change the immune system's tolerance so it can produce endogenesis cells to attack the virus.

Full Story:

Related Summaries